Takeda Pharmaceutical Co. Ltd.'s DPP-4 Treatment for Type 2 Diabetes Approved in China

Published: Aug 01, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

July 31, 2013 -- Takeda Pharma, Japan’s largest drugmaker, has been granted CFDA approval for Nesina (alogliptin), a treatment for type 2 diabetes. Nesina is a dipeptidyl peptidase-4 inhibitor (DPP-4). The DPP-4 drugs increase a person’s insulin response and offer both a low-side-effect profile and the convenience of oral administration. More details....

Stock Symbol: (TO: 4502)

Help employers find you! Check out all the jobs and post your resume.

Back to news